Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 73730P108 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Nomura Holdings Inc
13G/A
Amendment 1
|
0% |
5/15/2025
Event 3/31/2025
|
|
| Nomura Holdings Inc | 0% | ||
| Nomura Global Financial Products Inc | 0% | ||
|
Nomura Holdings Inc
13G
|
5.2% |
2/14/2025
Event 12/31/2024
|
|
| Nomura Holdings Inc | 5.2% | ||
| Nomura Global Financial Products Inc | 5.2% | ||
|
FMR LLC
13G/A
Amendment 6
|
0% |
2/7/2025
Event 1/31/2025
|
|
| FMR LLC | 0% | ||
| Abigail P. Johnson | 0% | ||
|
FMR LLC
13G/A
Amendment 5
|
10.3% |
2/7/2025
Event 12/31/2024
|
|
| FMR LLC | 10.3% | ||
| Abigail P. Johnson | 10.3% | ||
|
Malin Life Sciences Holdings Ltd
13G/A
Amendment 1
|
0% |
1/15/2025
Event 1/8/2025
|
|
| Malin Life Sciences Holdings Limited | 0% | ||
| Malin Corporation plc | 0% | ||
|
Pentwater Capital Management LP
13D/A
Amendment 3
|
0% |
1/13/2025
Event 1/8/2025
|
|
| Pentwater Capital Management LP | 0% | ||
| Matthew Halbower | 0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q1 | 2 | 100 k | $308 k |
| 2024 Q4 | 125 | 54.1 M | $519 M |
| 2024 Q3 | 102 | 53.7 M | $153 M |
| 2024 Q2 | 101 | 53.6 M | $156 M |
| 2024 Q1 | 100 | 54.0 M | $172 M |
| 2023 Q4 | 96 | 46.2 M | $155 M |
| 2023 Q3 | 91 | 45.2 M | $108 M |
| 2023 Q2 | 98 | 44.5 M | $78.4 M |
| 2023 Q1 | 105 | 44.1 M | $136 M |
| 2022 Q4 | 95 | 43.2 M | $228 M |
| 2022 Q3 | 72 | 40.1 M | $142 M |
| 2022 Q2 | 57 | 22.5 M | $58.1 M |
| 2022 Q1 | 67 | 24.2 M | $108 M |
| 2021 Q4 | 68 | 26.2 M | $179 M |
| 2021 Q3 | 69 | 26.2 M | $191 M |
| 2021 Q2 | 75 | 28.7 M | $287 M |
| 2021 Q1 | 65 | 29.7 M | $284 M |
| 2020 Q4 | 57 | 26.3 M | $288 M |
| 2020 Q3 | 53 | 25.4 M | $217 M |